Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

19.60 -0.22 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 7 Next >
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential. 
Via InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
Via Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
The 7 Best Stocks Under $15 to Buy in June 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount. 
Via InvestorPlace
Catalyst Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
1 Growth Stock to Buy Before the Next Bull Market
The stock is on a roll, and the company just made a major new purchase. 
Via The Motley Fool
Analyst Expectations for Catalyst Pharmaceuticals's Future
Via Benzinga
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context. 
Via The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
4 Analysts Have This to Say About Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Outlook For Catalyst Pharmaceuticals
Via Benzinga
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
7 A-Rated Stocks to Buy for April 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
These two drugmakers should march higher in 2023 and beyond. 
Via The Motley Fool
Why Catalyst Pharmaceuticals Shares Are Moving
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
2 Growth Stocks to Invest $1,000 in Right Now
Both of these biopharmas have major catalysts that are in play or drawing near. 
Via The Motley Fool
2 Breakout Growth Stocks to Buy for the Long Haul
These two stocks are entirely different, but they both make shareholders richer. 
Via The Motley Fool
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
7 Smart Stock Picks for Cautious Investors
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023
Via Benzinga
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.